Three of today's trials report progression-free or event-free survival as their primary result, and one reports overall survival that did not quite reach significance. The difference is where most miscommunication in oncology consultations begins.
Progression-free survival measures time until the scan changes or the patient dies. Overall survival measures time until the patient dies. They are not interchangeable, and in several tumour types a large progression-free survival gain has repeatedly failed to convert into any survival gain at all — because effective subsequent lines rescue the control arm, or because the endpoint captured a scan finding rather than a clinical event.
When a patient asks whether a drug will help them live longer, the accurate answer for most new agents is that it delays the disease getting worse, and whether it extends life is either unproven or unmeasured. That is not a discouraging answer if it is paired with what delay is worth: more time without symptoms, more time before the next treatment, more time before the next scan changes the conversation.
The practical habit is to name the endpoint aloud in the consultation and again in the notes. 'This adds about two and a half months before the disease progresses; whether it adds time overall is not yet known' is both truthful and usable. It also protects the patient later, when a scan does change and they need to understand that this was expected rather than a failure of the drug.
And apply the same discipline to event-free survival in haematology, where it bundles treatment failure, relapse and death into one number that is easy to over-read.
- Name the endpoint explicitly when quoting a benefit — progression-free, event-free or overall survival
- Do not translate a progression-free survival gain into a promise of longer life
- Quote absolute months rather than hazard ratios when speaking to patients
- Explain what delayed progression buys: symptom-free time and time before the next line of treatment
- Write the endpoint in the notes so the next clinician inherits the same framing
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free